GSK Launches Post-Marketing Safety Study for Recombinant Zoster Vaccine, Aiming to Enroll 3,300 Participants in China
GSK
Pharmaceutical R&D Manufacturer
On June 5, GSK initiated a post-marketing safety surveillance study of its recombinant zoster vaccine, planning to recruit 3,300 participants in China.
The recombinant zoster vaccine received conditional marketing approval from the NMPA in May 2019 for the prevention of herpes zoster in adults aged 50 years and older. The applicant is required to continue conducting comprehensive post-marketing studies, promptly carry out pharmacovigilance activities, update domestic and international clinical safety and efficacy data, and refine the package insert to fully ensure that patient medication is safe, effective, and with controllable risks.
The recombinant zoster vaccine is expected to be officially launched and sold in China in the near future. GSK stated that residents in Beijing and Shanghai will be the first to receive this vaccine in July this year.
*Disclaimer: This article was written by an author contributing to Sina Medical News. The views expressed are solely those of the author and do not represent the position of Sina Medical News.
